Xeljanz - IBD News Today
Xeljanz (tofacitinib) is a Janus kinase (JAK) inhibitor that has shown promise in Phase 3 clinical trials as a treatment for ulcerative colitis.
Source: ibdnewstoday.com
Page 13 - Clinical Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Clinical Development Program Today - Breaking & Trending Today
Daiichi Sankyo: ENHERTU Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
Approval based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca's ENHERTU reduced the risk of disease progression or death by 50% and increased median overall survival by more than
Source: finanznachrichten.de
ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...
Source: afp.com
Daiichi Sankyo: ENHERTU Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Daiichi Sankyo and AstraZeneca's ENHERTU also improved progression-free survival by 22 months versus T-DM1 in patients previously treated with HER2 directed therapy in the DESTINY-Breast03 phase
Source: finanznachrichten.de
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Source: prnewswire.com